INDV
NEUTRAL
$30.54
Live
Indivior Pharmaceuticals, Inc. · NASDAQ
Target $46.86
(+53.4%)
$8.69
52W Range
$38.0
At a glance
Key valuation, profitability, growth, and risk metrics.
Updated Apr 12, 2026
Market cap
$3.82B
P/E
18.62
ROE
N/A
Profit margin
16.9%
Debt/Equity
N/A
Dividend yield
N/A
AI Analysis
AI-powered fundamental assessment
Confidence
85%
INDV presents a stark contrast between operational excellence and financial fragility, highlighted by a weak Piotroski F-Score of 2/9. While the company exhibits explosive earnings growth (376% YoY) and trades significantly below its intrinsic value of $48.38, its balance sheet is highly distressed with a negative Price/Book ratio of -38.95 and a Current Ratio of 0.71. The forward P/E of 8.87 suggests an attractive valuation for growth, but the underlying solvency risks prevent a bullish rating. The investment thesis relies entirely on continued high-margin growth to offset structural financial weaknesses.
Key Strengths
Exceptional gross margins (84.02%) and operating margins (37.15%)
Explosive YoY earnings growth of 376.20%
Strong earnings track record with 3/4 recent quarters beating estimates
Significant valuation discount relative to intrinsic value ($48.38) and analyst targets ($46.86)
Strong 1-year price momentum (+241.6%)
Key Risks
Severe financial health warning indicated by Piotroski F-Score of 2/9
Negative shareholders' equity as evidenced by Price/Book of -38.95
Liquidity risk with a Current Ratio (0.71) and Quick Ratio (0.49) well below 1.0
Lack of dividend support or cash return profile
High dependency on specialty drug market stability
AI Fair Value Estimate
Based on comprehensive analysis
$42.5
+39.2% above current price
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Overall
54
Moderate
80
90
85
15
0
AI Verdict
High-Growth / High-Risk
Key drivers: Earnings growth, Balance sheet insolvency, Valuation gap
Confidence
90%
Value
80/100
Ref P/E, Forward P/E, and Intrinsic Value
Positives
- Forward P/E of 8.87 is very low
- Trading at ~37% discount to intrinsic value
Watchpoints
- Negative Book Value makes traditional P/B analysis impossible
Future
90/100
Ref YoY Revenue and Earnings Growth
Positives
- Consistent revenue growth (~20%)
- Massive EPS acceleration
Watchpoints
- Sustainability of 300%+ growth rates
Past
85/100
Ref Price Performance Snapshot
Positives
- Strong 5Y (+218%) and 1Y (+241%) returns
- Consistent history of earnings surprises
Watchpoints
No urgent risks highlighted.
Health
15/100
Ref Piotroski F-Score and Liquidity Ratios
Positives
- Strong ROA (19.22%)
Watchpoints
- Piotroski F-Score 2/9
- Current Ratio < 1.0
- Negative Equity
Dividend
0/100
Ref Dividend Yield and Payout Ratio
Positives
No standout positives identified.
Watchpoints
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Current Price
$30.54
Analyst Target
$46.86
Upside/Downside
+53.4%
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for INDV and closest competitors.
Updated 2026-04-10
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals, Inc.
Primary
|
+218.1% | +75.0% | +241.6% | +28.4% | -7.0% | +0.2% |
|
ALHC
Alignment Healthcare, Inc.
Peer
|
+11.0% | +93.4% | +42.7% | +17.5% | -12.9% | -6.7% |
|
IRTC
iRhythm Holdings, Inc.
Peer
|
+43.4% | -13.2% | +16.6% | -34.6% | -3.7% | -1.3% |
|
AMRX
Amneal Pharmaceuticals, Inc.
Peer
|
+69.5% | +727.3% | +34.6% | +18.3% | -19.5% | -10.7% |
|
ADMA
ADMA Biologics, Inc.
Peer
|
+604.6% | +370.5% | -15.4% | -6.0% | -6.9% | -1.6% |
IND
Indivior Pharmaceuticals, Inc.
Primary
5Y
+218.1%
3Y
+75.0%
1Y
+241.6%
6M
+28.4%
1M
-7.0%
1W
+0.2%
ALH
Alignment Healthcare, Inc.
Peer
5Y
+11.0%
3Y
+93.4%
1Y
+42.7%
6M
+17.5%
1M
-12.9%
1W
-6.7%
IRT
iRhythm Holdings, Inc.
Peer
5Y
+43.4%
3Y
-13.2%
1Y
+16.6%
6M
-34.6%
1M
-3.7%
1W
-1.3%
AMR
Amneal Pharmaceuticals, Inc.
Peer
5Y
+69.5%
3Y
+727.3%
1Y
+34.6%
6M
+18.3%
1M
-19.5%
1W
-10.7%
ADM
ADMA Biologics, Inc.
Peer
5Y
+604.6%
3Y
+370.5%
1Y
-15.4%
6M
-6.0%
1M
-6.9%
1W
-1.6%
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Historical data shows last 12 quarters (3 years)
Valuation Metrics
Key valuation ratios and pricing indicators
P/E Ratio
18.62
Forward P/E
8.87
PEG Ratio
N/A
P/B Ratio
-38.95
P/S Ratio
3.08
EV/Revenue
3.21
EV/EBITDA
10.01
Market Cap
$3.82B
Profitability
Profit margins and return metrics
Profit Margin
16.95%
Operating Margin
37.15%
Gross Margin
84.02%
ROE
N/A
ROA
19.22%
Growth
Revenue and earnings growth rates
Revenue Growth
+19.7%
Earnings Growth
+376.2%
Q/Q Revenue Growth
+19.73%
Q/Q Earnings Growth
+385.7%
Financial Health
Balance sheet strength and liquidity metrics
Debt/Equity
N/A
Current Ratio
0.71
Weak
Quick Ratio
0.49
Poor
Cash/Share
$1.56
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Revenue
$0.4B
Gross Margin
81.3%
Op. Margin
23.2%
Net Margin
28.5%
Total Assets
$1.2B
Liabilities
$1.3B
Equity
$-0.1B
Debt/Equity
-13.13x
Operating CF
$-0.2B
CapEx
$-0.0B
Free Cash Flow
$-0.2B
FCF Yield
111%
Quarterly Earnings History
EPS performance vs analyst estimates
2026-04-30
$N/A
2026-02-26
$0.82
+21.7% surprise
2025-10-30
$0.72
+74.9% surprise
2025-07-31
$0.51
+104.0% surprise
Healthcare Sector Comparison
Comparing INDV against 264 companies in the Healthcare sector
(20 bullish, 87 neutral, 157 bearish)
P/E Ratio
18.62
This Stock
vs
88.64
Sector Avg
-79.0%
(Discount)
Profit Margin
16.95%
This Stock
vs
-19.58%
Sector Avg
-186.5%
(Weaker)
Revenue Growth
19.7%
This Stock
vs
88.16%
Sector Avg
-77.7%
(Slower)
Current Ratio
0.71
This Stock
vs
3.58
Sector Avg
-80.1%
(Weaker)
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
INDV
Indivior Pharmaceuticals, Inc.
|
NEUTRAL | $3.82B | 18.62 | -% | 16.9% | $30.54 | |
|
ALHC
Alignment Healthcare, Inc.
|
BEARISH | $3.85B | - | -0.7% | -0.0% | $19.22 | Compare |
|
IRTC
iRhythm Holdings, Inc.
|
NEUTRAL | $3.72B | - | -36.6% | -6.0% | $115.24 | Compare |
|
AMRX
Amneal Pharmaceuticals, Inc.
|
BEARISH | $3.72B | 53.77 | -% | 2.4% | $11.83 | Compare |
|
ADMA
ADMA Biologics, Inc.
|
BEARISH | $3.61B | 25.25 | 35.6% | 28.8% | $15.15 | Compare |
INDV
Indivior...
NEUTRAL
Mkt Cap
$3.8B
P/E
18.6
ROE
-%
Price
$30.54
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-13 | RYAN BARBARA A. | Director | Purchase | 8 | $249 |
| 2026-03-13 | PREBLICK RYAN | Chief Financial Officer | Stock Award | 6,302 | - |
| 2026-03-09 | RYAN BARBARA A. | Director | Purchase | 31 | $1,009 |
| 2026-03-06 | KINGSLEY STUART A | Director | Purchase | 940 | $29,953 |
| 2026-03-03 | BURRIS JEFFREY W | Officer | Stock Award | 79,893 | - |
| 2026-03-03 | HEIDBREDER CHRISTIAN | Officer | Stock Award | 101,544 | - |
| 2026-03-03 | ANDERSON WOODROW D | Officer | Stock Award | 24,310 | - |
| 2026-03-03 | PREBLICK RYAN | Chief Financial Officer | Stock Award | 86,949 | - |
| 2026-02-10 | CIAFFONI JOSEPH J | Chief Executive Officer | Stock Award | 79,976 | - |
| 2026-02-10 | BURRIS JEFFREY W | Officer | Stock Award | 26,897 | - |
| 2026-02-10 | BARRY PATRICK A | Officer | Stock Award | 31,380 | - |
| 2026-02-10 | HEIDBREDER CHRISTIAN | Officer | Stock Award | 33,622 | - |
| 2026-02-10 | ANDERSON WOODROW D | Officer | Stock Award | 6,903 | - |
| 2026-02-10 | PREBLICK RYAN | Chief Financial Officer | Stock Award | 37,358 | - |
| 2026-01-26 | NINIVAGGI DANIEL A | Director | Stock Award | 3,722 | - |
RYAN BARBARA A.
Director
2026-03-13
8 shares
·
$249
PREBLICK RYAN
Chief Financial Officer
2026-03-13
6,302 shares
RYAN BARBARA A.
Director
2026-03-09
31 shares
·
$1,009
KINGSLEY STUART A
Director
2026-03-06
940 shares
·
$29,953
BURRIS JEFFREY W
Officer
2026-03-03
79,893 shares
HEIDBREDER CHRISTIAN
Officer
2026-03-03
101,544 shares
ANDERSON WOODROW D
Officer
2026-03-03
24,310 shares
PREBLICK RYAN
Chief Financial Officer
2026-03-03
86,949 shares
CIAFFONI JOSEPH J
Chief Executive Officer
2026-02-10
79,976 shares
BURRIS JEFFREY W
Officer
2026-02-10
26,897 shares
BARRY PATRICK A
Officer
2026-02-10
31,380 shares
HEIDBREDER CHRISTIAN
Officer
2026-02-10
33,622 shares
ANDERSON WOODROW D
Officer
2026-02-10
6,903 shares
PREBLICK RYAN
Chief Financial Officer
2026-02-10
37,358 shares
NINIVAGGI DANIEL A
Director
2026-01-26
3,722 shares
Insider transactions can signal confidence or concerns about company prospects
Wall Street Analysts
Professional analyst ratings and price targets
Consensus
NONE
7 analysts
HC Wainwright & Co.
2026-01-12
Buy
Buy
Piper Sandler
2025-10-31
Overweight
Overweight
HC Wainwright & Co.
2025-10-30
Buy
Buy
Past News Coverage
Recent headlines mentioning INDV from our newsroom.
Newest → oldest
No matching news yet.